SAN JOSE, Calif., May 29, 2019 /PRNewswire/ -- Anixa
Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused
on using the body's immune system to fight cancer, today announced
that it will present updated data from its study utilizing Cchek™,
its artificial intelligence (AI) driven early cancer detection
technology, at CYTO 2019 – 34th Congress of the
International Society for Advancement of Cytometry (ISAC) in
Vancouver, BC, Canada. The
conference will be held June 22-26,
2019 and will be attended by world leading experts across
the field of cytometry.
Presentation details:
Title:
|
Combining Machine
Learning (ML) with Flow Cytometry Based Immunophenotyping: A Novel
Liquid Biopsy Aid for Identifying the Risk for Prostate Cancer
(PCa)
|
|
|
First
Author:
|
George A. Dominguez,
PhD, Senior Clinical Research Scientist
|
|
|
Viewing
Times:
|
Monday, June
24 8:00 a.m. – 6:00 p.m.
|
|
Tuesday, June
25 8:00 a.m. – 6:00 p.m.
|
|
Wednesday, June 26
8:00 a.m. – 4:00
p.m.
|
|
|
Presenting
Time:
|
Tuesday, June
25 4:30 p.m. – 6:00 p.m.
|
|
|
Program
No.:
|
340
|
|
|
Poster Board
No.:
|
B202
|
The presentation will focus on the continuing progress of
Anixa's Cchek™ technology that combines the fields of flow
cytometry with artificial intelligence, featuring new data and
insights into its application for early prostate cancer
detection.
"We are pleased to continue presenting data, on our liquid
biopsy technology for early cancer detection, as we progress toward
the launch of our first commercial test for prostate cancer,"
stated Amit Kumar, PhD, President
and CEO of Anixa Biosciences.
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company focused on harnessing the
body's immune system in the fight against cancer. Anixa is
developing a cancer immunotherapy program, which uses chimeric
endocrine receptor t-cell (CER-T) technology, a novel type of
CAR-T. It is also developing the Cchek™ liquid
biopsy technology, a series of inexpensive non-invasive blood tests
for early detection of solid tumors based on the body's immune
response to the presence of a malignancy. This technology
enables cancer detection in its earliest stages in efforts to treat
patients when the disease is most curable. Additional
information is available at www.anixa.com.
About International Society for Advancement of Cytometry
(ISAC)
The International Society for Advancement of
Cytometry (ISAC) (https://isac-net.org) is a 501(c)(3) organization
based in Arlington, VA. The purpose of the ISAC is to
promote: development of cytometry; transfer of methodologies;
and exchange scientific and technical information. Cytometry
is broadly defined as the characterization and measurement of cells
and cellular constituents for biological, diagnostic and
therapeutic purposes.
Forward-Looking Statements: Statements
that are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We
generally use the words "believes," "expects," "intends," "plans,"
"anticipates," "likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You
are cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
release.
Anixa contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
Tiberend Strategic Advisors, Inc.
Sharen Tilman (Investors)
stilman@tiberend.com
646-604-5149
Ingrid Mezo (Media)
imezo@tiberend.com
646-604-5150
View original content to download
multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-to-present-at-the-cyto-2019--34th-congress-of-the-international-society-for-advancement-of-cytometry-300857915.html
SOURCE Anixa Biosciences, Inc.